Faeth Therapeutics, Inc. (FTH) · Oct 27, 2026 · Exec change
Oncology R&D director — Board expanded from six to seven; 25,000-share option granted
Faeth Therapeutics appoints oncology development veteran Adam Schayowitz as a director, strengthening oversight as PIKTOR moves toward major clinical milestones.
Faeth is a newly reshaped clinical-stage oncology company built around PIKTOR, an all-oral combination targeting the PI3K/AKT/mTOR pathway, with a Phase 2 endometrial-cancer study and a planned breast-cancer program as its next major proof points. This appointment adds development and commercialization depth, not a new clinical asset. Adam Schayowitz brings recent senior R&D leadership at Zymeworks and prior oncology development experience at Pfizer and Tesaro; the filing specifically cites his background in “oncology drug development, clinical and regulatory strategy and commercialization.” 〔0〕 The timing fits Faeth’s shift from rebuilding the corporate platform toward executing clinical milestones. The board now has seven directors, following another oncology-focused appointment in September, so the direction was becoming visible before this filing; the new information is the specific addition of a hands-on drug-development operator. The economic commitment is modest and standard. Schayowitz receives the normal director retainer plus an option for 25,000 shares, vesting monthly over three years and accelerating upon a change in control. Bottom line: This is a sensible governance upgrade ahead of PIKTOR’s clinical readouts, but it does not change the drug’s evidence, financing, or development timetable today. Its value is execution support rather than a new business catalyst by itself.
PIKTOR Phase 2 endometrial data, expected by year-end 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!